Translational Development Acquisition (TDACU) Stock Price, News & Analysis

Company Overview

Trident Acquisitions Corp. does not have significant operations. It intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses primarily in the oil and gas or other natural resource sector. Trident Acquisitions Corp. was incorporated in 2016 and is headquartered in New York, New York.

Key Stats

• Today's Range: $10.10 to $10.13
• 50-Day Range: $10.01 to $10.13
• 52-Week Range: $10.00 to $10.30
• Volume: 333 shs
• Average Volume: 40,754 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TDACU Stock Analysis - Frequently Asked Questions

How have TDACU shares performed this year?

Translational Development Acquisition's stock was trading at $10.02 at the beginning of 2025. Since then, TDACU shares have increased by 1.1% and is now trading at $10.13.
View the best growth stocks for 2025 here.

When did Translational Development Acquisition IPO?

Translational Development Acquisition (TDACU) raised $150 million in an initial public offering (IPO) on the week of December 23rd 2024. The company issued 15,000,000 shares at a price of $10.00 per share.

When did the company's quiet period expire?

Translational Development Acquisition's quiet period expired on Monday, February 3rd. Translational Development Acquisition had issued 15,000,000 shares in its public offering on December 23rd. The total size of the offering was $150,000,000 based on an initial share price of $10.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Translational Development Acquisition's major shareholders?

Translational Development Acquisition's top institutional shareholders include AQR Arbitrage LLC, Magnetar Financial LLC, LMR Partners LLP and Polar Asset Management Partners Inc..

How do I buy shares of Translational Development Acquisition?

Shares of TDACU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Finance, Insurance, And Real Estate
• Industry: Investment Offices
• Sub-Industry: Trading
• Current Symbol: NASDAQ:TDACU
• CUSIP: N/A
• CIK: 1926599
• Web: N/A
• Phone: (413) 204-2769
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $5.64 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A